Accessibility Menu
 

Cyclopharm

(ASX) CYC

Current Price$0.80
Market Cap$96.64M
Since IPO (2007)-48%
5 Year-69%
1 Year-29%
1 Month+4%

Cyclopharm Financials at a Glance

Market Cap

$96.64M

Revenue (TTM)

$58.97M

Net Income (TTM)

$30.42M

EPS (TTM)

$-0.16

P/E Ratio

-5.15

Dividend

$0.00

Beta (Volatility)

0.02 (Low)

Price

$0.80

Volume

93,348

Open

$0.83

Previous Close

$0.80

Daily Range

$0.80 - $0.83

52-Week Range

$0.56 - $1.48

CYC News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Cyclopharm

Industry

Healthcare Equipment and Supplies

Employees

109

CEO

James M. McBrayer

Headquarters

Kingsgrove, NSW 2208, AU

CYC Financials

Key Financial Metrics (TTM)

Gross Margin

24%

Operating Margin

-56%

Net Income Margin

-53%

Return on Equity

-49%

Return on Capital

-52%

Return on Assets

-37%

Earnings Yield

-19.42%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$96.64M

Shares Outstanding

120.80M

Volume

93.35K

Short Interest

0.00%

Avg. Volume

139.34K

Financials (TTM)

Gross Profit

$1.46M

Operating Income

$18.18M

EBITDA

$16.41M

Operating Cash Flow

$17.33M

Capital Expenditure

$1.99M

Free Cash Flow

$19.32M

Cash & ST Invst.

$6.63M

Total Debt

$14.92M

Cyclopharm Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

$16.90M

+59.2%

Gross Profit

$462.21K

+50.3%

Gross Margin

-2.73%

N/A

Market Cap

$96.64M

N/A

Market Cap/Employee

$1.02M

N/A

Employees

95

N/A

Net Income

$9.53M

-427.9%

EBITDA

$8.48M

-791.2%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Net Cash

$8.29M

-210.6%

Accounts Receivable

$8.59M

+8.8%

Inventory

$11.43M

+13.0%

Long Term Debt

$14.36M

+257.8%

Short Term Debt

$561.17K

+30.8%

Return on Assets

-37.35%

N/A

Return on Invested Capital

-52.30%

N/A

Free Cash Flow

$11.62M

-90.2%

Operating Cash Flow

$9.83M

-69.3%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
ATX.AXAmplia Therapeutics Limited
$0.15+0.00%
M7T.AXMach7 Technologies Limited
$0.31-3.13%
CYP.AXCynata Therapeutics Limited
$0.29+1.72%
CMP.AXCompumedics Limited
$0.28+1.82%

Trending Stocks

Symbol / CompanyPricePrice Chg
CRWVCoreWeave
$103.74+0.13%
NOKNokia
$9.52-0.00%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$10.43-0.00%
TQQQProShares Trust - ProShares UltraPro Qqq
$49.38+0.01%

Questions About CYC

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.